Meri S - Search Results

1

Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.

Harjunpää A, Taskinen M, Nykter M, Karjalainen-Lindsberg ML, Nyman H, Monni O, Hemmer S, Yli-Harja O, Hautaniemi S, Meri S, Leppä S. Harjunpää A, et al. Among authors: meri s. Br J Haematol. 2006 Oct;135(1):33-42. doi: 10.1111/j.1365-2141.2006.06255.x. Epub 2006 Aug 22. Br J Haematol. 2006. PMID: 16925574 Free article.

2

Complement activation in the central nervous system following blood-brain barrier damage in man.

Lindsberg PJ, Ohman J, Lehto T, Karjalainen-Lindsberg ML, Paetau A, Wuorimaa T, Carpén O, Kaste M, Meri S. Lindsberg PJ, et al. Among authors: meri s. Ann Neurol. 1996 Oct;40(4):587-96. doi: 10.1002/ana.410400408. Ann Neurol. 1996. PMID: 8871578

3

Serum complement and familial combined hyperlipidemia.

Ylitalo K, Porkka KV, Meri S, Nuotio I, Suurinkeroinen L, Vakkilainen J, Pajukanta P, Viikari JS, Peltonen L, Ehnholm C, Taskinen MR. Ylitalo K, et al. Among authors: meri s. Atherosclerosis. 1997 Mar 21;129(2):271-7. doi: 10.1016/s0021-9150(96)06054-6. Atherosclerosis. 1997. PMID: 9105570

4

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.

Harjunpää A, Junnikkala S, Meri S. Harjunpää A, et al. Among authors: meri s. Scand J Immunol. 2000 Jun;51(6):634-41. doi: 10.1046/j.1365-3083.2000.00745.x. Scand J Immunol. 2000. PMID: 10849376 Free article.

5

Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia.

Ylitalo K, Pajukanta P, Meri S, Cantor RM, Mero-Matikainen N, Vakkilainen J, Nuotio I, Taskinen MR. Ylitalo K, et al. Among authors: meri s. Arterioscler Thromb Vasc Biol. 2001 May;21(5):838-43. doi: 10.1161/01.atv.21.5.838. Arterioscler Thromb Vasc Biol. 2001. PMID: 11348883

6

Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.

Harjunpää A, Wiklund T, Collan J, Janes R, Rosenberg J, Lee D, Grillo-López A, Meri S. Harjunpää A, et al. Among authors: meri s. Leuk Lymphoma. 2001 Aug;42(4):731-8. doi: 10.3109/10428190109099335. Leuk Lymphoma. 2001. PMID: 11697503

7

Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.

Mattila AM, Meri S. Mattila AM, et al. Among authors: meri s. Scand J Immunol. 2008 Aug;68(2):159-68. doi: 10.1111/j.1365-3083.2008.02129.x. Scand J Immunol. 2008. PMID: 18702746 Free article.

8

Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.

Taskinen M, Valo E, Karjalainen-Lindsberg ML, Hautaniemi S, Meri S, Leppä S. Taskinen M, et al. Among authors: meri s. Clin Cancer Res. 2010 May 1;16(9):2615-23. doi: 10.1158/1078-0432.CCR-09-3269. Epub 2010 Apr 13. Clin Cancer Res. 2010. PMID: 20388848

9

Diagnosis of atypical neurocysticercosis by polymerase chain reaction analysis: case report.

Meri T, Jokiranta TS, Granat S, Collander F, Valtonen M, Meri S. Meri T, et al. Among authors: meri s. Clin Infect Dis. 1999 Jun;28(6):1331-2. doi: 10.1086/517790. Clin Infect Dis. 1999. PMID: 10451184 No abstract available.

10

Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjørge L, Bützow R, Zipfel PF, Meri S. Junnikkala S, et al. Among authors: meri s. Br J Cancer. 2002 Nov 4;87(10):1119-27. doi: 10.1038/sj.bjc.6600614. Br J Cancer. 2002. PMID: 12402151 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

381 results

Search Page